Clinical Trial Update: A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension [Phase 4]

View source ↗

Summary

Phase 4 study evaluating 0.03% bimatoprost for primary open-angle glaucoma and ocular hypertension. The study completed and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Lumigan (bimatoprost)

Snippet

Sponsor: Allergan | Conditions: Glaucoma, Open-Angle, Ocular Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2014-07-21